不同体液标本活检在肺癌微小残留疾病监测中的应用最新进展  

Different Body Fluid Biopsies for Detecting Minimal Residual Disease in Lung Cancer:a Review of the Latest Advances

作　　者：闫星 刘山梅 刘长宏[1] YAN Xing;LIU Shanmei;LIU Changhong(Department of Thoracic Surgery,the Second Hospital of Dalian Medical University,Dalian 116000,China;Inner Mongolia Medical University,Hohhot 015000,China)

机构地区：[1]大连医科大学第二附属医院胸外科,辽宁省大连市116000 [2]内蒙古医科大学,内蒙古自治区呼和浩特市015000

出　　处：《中国全科医学》2023年第3期280-286,共7页Chinese General Practice

基　　金：辽宁省自然科学基金资助项目(20180550364)。

摘　　要：肺癌是世界上致死率最高的恶性肿瘤之一,治疗后复发是其难以攻克的主要原因。微小残留疾病(MRD)作为实体瘤复发的“桥头堡”,被描述为治疗原发肿瘤后,在没有任何癌症临床症状的情况下,患者的生物液体中仍然存在游离的循环肿瘤细胞或其他肿瘤细胞衍生物。2021年中国达成了首个“肺癌MRD的检测和临床应用共识”,旨在通过液体活检监测以评估肺癌患者MRD状态,进而完善其术后个体化治疗。本文综述了几种热点液体(外周血、尿液、唾液、痰液、胸腔积液)标本在肺癌MRD检测中的进展,并探讨其指导肺癌MRD精准治疗的应用价值。Post-treatment recurrence is a major difficulty in the treatment of lung cancer,one of the deadliest cancers worldwide.Minimal residual disease(MRD)as a“bridgehead”for the recurrence of solid tumors,is described as the presence of free circulating tumor cells or other tumor cell derivatives in the biological fluid of patients without any clinical cancer symptoms after the primary tumor treatment.China recently issued its first Consensus on the Detection and Clinical Application of MRD in Lung Cancer,aiming at improving the postoperative individualized treatment for lung cancer patients in accordance with the MRD status detected by the liquid biopsy.We reviewed the latest advances in the use of several most widely used body fluids(peripheral blood,urine,saliva,sputum and pleural effusion)in the detection of MRD in lung cancer,and discussed their values in guiding the precise treatment of MRD in lung cancer.

关 键 词：肺肿瘤 液体活组织检查 肿瘤 残留 循环肿瘤DNA 综述 

分 类 号：R734.2[医药卫生—肿瘤]